Professur für Translationale Frauenheilkunde und Geburtshilfe

Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study (2025) Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, et al. Journal article Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer (2025) Walter CB, Hartkopf AD, Hein A, Fasching P, Kolberg HC, Hadji P, Tesch H, et al. Journal article Fully automatic HER2 tissue segmentation for interpretable HER2 scoring (2025) Öttl M, Steenpaß J, Wilm F, Qiu J, Rübner M, Lang-Schwarz C, Taverna C, et al. Journal article Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations (2025) Schulmeyer C, Fasching P, Beckmann M, Häberle L, Golcher H, Goebell P, Pöschke P, Emons J Journal article RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial (2025) Villacampa G, Llop-Guevara A, Filmann N, Herencia-Ropero A, Fasching P, Karn T, Marmé F, et al. Journal article Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact (2025) Hübner H, Wimberger P, Laakmann E, Ruckhäberle E, Rübner M, Lehle S, Uhrig S, et al. Journal article A Swedish genome-wide haplotype association analysis identifies novel candidate loci associated with endometrial cancer risk (2025) Barnekow E, Liu W, Andersson E, Wang X, Helgadottir HT, Thutkawkorapin J, Barilla S, et al. Journal article Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping (2025) Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, et al. Journal article A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article Genome-Wide Association Analyses of HPV16 and HPV18 Seropositivity Identify Susceptibility Loci for Cervical Cancer (2025) Beckhaus T, Kachuri L, Nakase T, Schürmann P, Eisenblätter R, Geerts M, Böhmer G, et al. Journal article